170632-47-0 | Lificiguat

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$14.00	$10.00
5mg	98%	in stock	$35.00	$25.00
50mg	98%	in stock	$139.00	$98.00

Description

• Catalog Number: AE98727
• Chemical Name: Lificiguat
• CAS Number: 170632-47-0
• Molecular Formula: C19H16N2O2
• Molecular Weight: 304.3425
• MDL Number: MFCD06407798
• SMILES: OCc1ccc(o1)c1nn(c2c1cccc2)Cc1ccccc1
• NSC Number: 728165

Computed Properties

• Complexity: 386
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 23
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 4
• XLogP3: 3.1

Literature

• Diaryl-substituted ortho-carboranes as a new class of hypoxia inducible factor-1α inhibitors.

  Dalton transactions (Cambridge, England : 2003) 20140407

• Dysfunctional nitric oxide signalling increases risk of myocardial infarction.

  Nature 20131219

• MicroRNA-210 targets antiapoptotic Bcl-2 expression and mediates hypoxia-induced apoptosis of neuroblastoma cells.

  Archives of toxicology 20130301

• The effect of 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole (YC-1) on cell viability under hypoxia.

  Molecular vision 20130101

• Hypoxia regulates the expression of the neuromedin B receptor through a mechanism dependent on hypoxia-inducible factor-1α.

  PloS one 20130101

• Nitric oxide, can it be only good? Increasing the antioxidant properties of nitric oxide in hepatocytes by YC-1 compound.

  Nitric oxide : biology and chemistry 20121201

• YC-1, a potent antithrombotic agent, induces lipolysis through the PKA pathway in rat visceral fat cells.

  European journal of pharmacology 20120815

• Lipopolysaccharide and hypoxia-induced HIF-1 activation in human gingival fibroblasts.

  Journal of periodontology 20120601

• Guanylate cyclase activator YC-1 potentiates apoptotic effect of licochalcone A on human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathways.

  European journal of pharmacology 20120515

• Inhibition of hypoxia inducible factor-1α ameliorates lung injury induced by trauma and hemorrhagic shock in rats.

  Acta pharmacologica Sinica 20120501

• YC-1 exerts inhibitory effects on MDA-MB-468 breast cancer cells by targeting EGFR in vitro and in vivo under normoxic condition.

  Chinese journal of cancer 20120501

• YC-1 potentiates cAMP-induced CREB activation and nitric oxide production in alveolar macrophages.

  Toxicology and applied pharmacology 20120415

• HIF-1α coordinates lymphangiogenesis during wound healing and in response to inflammation.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20120301

• Mechanisms underlying somatostatin receptor 2 down-regulation of vascular endothelial growth factor expression in response to hypoxia in mouse retinal explants.

  The Journal of pathology 20120201

• Hypoxia inducible factor-1α contributes to UV radiation-induced inflammation, epidermal hyperplasia and immunosuppression in mice.

  Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology 20120201

• Hypoxia-derived oxidative stress mediates epigenetic repression of PKCε gene in foetal rat hearts.

  Cardiovascular research 20120201

• HIF-1 is involved in high glucose-induced paracellular permeability of brain endothelial cells.

  Cellular and molecular life sciences : CMLS 20120101

• Effects of YC-1 on hypoxia-inducible factor 1 alpha in hypoxic human bladder transitional carcinoma cell line T24 cells.

  Urologia internationalis 20120101

• HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast.

  BMC cancer 20120101

• Up-regulation of hypoxia inducible factor-1α by cobalt chloride correlates with proliferation and apoptosis in PC-2 cells.

  Journal of experimental & clinical cancer research : CR 20120101

• Hypoxia-inducible factor 1 protects hypoxic astrocytes against glutamate toxicity.

  ASN neuro 20120101

• Insufficient radiofrequency ablation promotes angiogenesis of residual hepatocellular carcinoma via HIF-1α/VEGFA.

  PloS one 20120101

• YC-1 targeting of hypoxia-inducible factor-1α reduces RGC-5 cell viability and inhibits cell proliferation.

  Molecular vision 20120101

• YC-1, a novel potential anticancer agent, inhibit multidrug-resistant protein via cGMP-dependent pathway.

  Investigational new drugs 20111201

• Blockade of hypoxia-inducible factor-1α by YC-1 attenuates interferon-γ and tumor necrosis factor-α-induced intestinal epithelial barrier dysfunction.

  Cytokine 20111201

• YC-1 attenuates hypoxia-induced pulmonary arterial hypertension in mice.

  Pulmonary pharmacology & therapeutics 20111201

• Hypoxia-inducible factor-1α is essential for hypoxia-induced mesenchymal stem cell mobilization into the peripheral blood.

  Stem cells and development 20111101

• Hypoxia-inducible factor 1 mediates increased expression of NADPH oxidase-2 in response to intermittent hypoxia.

  Journal of cellular physiology 20111101

• Acidic triazoles as soluble guanylate cyclase stimulators.

  Bioorganic & medicinal chemistry letters 20111101

• Design, synthesis and insight into the structure-activity relationship of 1,3-disubstituted indazoles as novel HIF-1 inhibitors.

  Bioorganic & medicinal chemistry letters 20111101

• Guanylate cyclase activator YC-1 enhances TRAIL-induced apoptosis in human epithelial ovarian carcinoma cells via activation of apoptosis-related proteins.

  Basic & clinical pharmacology & toxicology 20111001

• Impact of hypoxia on the metastatic potential of human prostate cancer cells.

  International journal of radiation oncology, biology, physics 20111001

• Endothelium-dependent vasoconstriction in isolated vessel grafts: a novel mechanism of vasospasm?

  The Annals of thoracic surgery 20111001

• The soluble guanylyl cyclase activator YC-1 increases intracellular cGMP and cAMP via independent mechanisms in INS-1E cells.

  The Journal of pharmacology and experimental therapeutics 20110901

• Activity of guanylyl cyclase activators on the reaction of tracheal smooth muscle contraction.

  Postepy higieny i medycyny doswiadczalnej (Online) 20110805

• Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part II.

  Archivum immunologiae et therapiae experimentalis 20110801

• Aspartate 102 in the heme domain of soluble guanylyl cyclase has a key role in NO activation.

  Biochemistry 20110524

• Protective effects of YC-1 against glutamate induced PC12 cell apoptosis.

  Cellular and molecular neurobiology 20110301

• Hypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004 - 2010).

  Expert opinion on therapeutic patents 20110201

• The nitric oxide-cGMP signaling pathway plays a significant role in tolerance to the analgesic effect of morphine.

  Canadian journal of physiology and pharmacology 20110201

• Inhibition of reactive gliosis prevents neovascular growth in the mouse model of oxygen-induced retinopathy.

  PloS one 20110101

• Up-regulation of hypoxia-inducible factor-1 alpha by cobalt chloride prevents hearing loss in noise-exposed mice.

  Environmental toxicology and pharmacology 20110101

• [Inhibition of no-dependent soluble human platelet guanylate cyclase by isatin].

  Biomeditsinskaia khimiia 20110101

• Differential effects of HIF-1 inhibition by YC-1 on the overall outcome and blood-brain barrier damage in a rat model of ischemic stroke.

  PloS one 20110101

• Involvement of YC-1 in extracellular signal-regulated kinase action in rat cremasteric muscle.

  The Journal of pharmacy and pharmacology 20101201

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• Efficient two-step sequence for the synthesis of 2,5-disubstituted furan derivatives from functionalized nitroalkanes: successive Amberlyst A21- and Amberlyst 15-catalyzed processes.

  Chemical communications (Cambridge, England) 20100907

• Binding of YC-1/BAY 41-2272 to soluble guanylate cyclase: A new perspective to the mechanism of activation.

  Biochemical and biophysical research communications 20100702

• Suppression of hypoxia-inducible factor-1alpha and its downstream genes reduces acute hyperglycemia-enhanced hemorrhagic transformation in a rat model of cerebral ischemia.

  Journal of neuroscience research 20100701

• Soluble guanylate cyclase is activated differently by excess NO and by YC-1: resonance Raman spectroscopic evidence.

  Biochemistry 20100615

• Insulin promotes proliferative vitality and invasive capability of pancreatic cancer cells via hypoxia-inducible factor 1alpha pathway.

  Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20100601

• Probing soluble guanylate cyclase activation by CO and YC-1 using resonance Raman spectroscopy.

  Biochemistry 20100511

• Preconditioning protects against oxidative injury involving hypoxia-inducible factor-1 and vascular endothelial growth factor in cultured astrocytes.

  European journal of pharmacology 20100510

• Development of nitrergic neurons in the nervous system of the locust embryo.

  The Journal of comparative neurology 20100415

• YC-1 enhances natural killer cell differentiation from hematopoietic stem cells.

  International immunopharmacology 20100401

• Reverse phase protein array identifies novel anti-invasion mechanisms of YC-1.

  Biochemical pharmacology 20100315

• Pleiotropic effects of YC-1 selectively inhibit pathological retinal neovascularization and promote physiological revascularization in a mouse model of oxygen-induced retinopathy.

  Molecular pharmacology 20100301

• The effect of hypoxia-inducible factor 1-alpha on hypoxia-induced apoptosis in primary neonatal rat ventricular myocytes.

  Cardiovascular journal of Africa 20100201

• HIF-1alpha and cancer therapy.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20100101

• The guanylyl cyclase activator YC-1 directly inhibits the voltage-dependent K+ channels in rabbit coronary arterial smooth muscle cells.

  Journal of pharmacological sciences 20100101

• Modulating the hypoxia-inducible factor signaling pathway as a therapeutic modality to regulate retinal angiogenesis.

  Experimental eye research 20091101

• Digoxin and ouabain induce P-glycoprotein by activating calmodulin kinase II and hypoxia-inducible factor-1alpha in human colon cancer cells.

  Toxicology and applied pharmacology 20091101

• Presence of cyclic nucleotide-gated channels in the rat urethra and their involvement in nerve-mediated nitrergic relaxation.

  American journal of physiology. Renal physiology 20091101

• Combined application of camptothecin and the guanylate cyclase activator YC-1: Impact on cell death and apoptosis-related proteins in ovarian carcinoma cell lines.

  Chemico-biological interactions 20091007

• Using YC-1 to overcome the radioresistance of hypoxic cancer cells.

  Oral oncology 20091001

• Involvement of Ras/Raf-1/p44/42 MAPK in YC-1-induced cyclooxygenase-2 expression in human pulmonary epithelial cells.

  Pharmacological research 20091001

• Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.

  Nature chemical biology 20091001

• Hypoxia up-regulates CD36 expression and function via hypoxia-inducible factor-1- and phosphatidylinositol 3-kinase-dependent mechanisms.

  The Journal of biological chemistry 20090925

• Phosphodiesterase 5 restricts NOS3/Soluble guanylate cyclase signaling to L-type Ca2+ current in cardiac myocytes.

  Journal of molecular and cellular cardiology 20090801

• L-DOPA inhibits nitric oxide-dependent vasorelaxation via production of reactive oxygen species in rat aorta.

  The journal of medical investigation : JMI 20090801

• Human trabecular meshwork cell volume decrease by NO-independent soluble guanylate cyclase activators YC-1 and BAY-58-2667 involves the BKCa ion channel.

  Investigative ophthalmology & visual science 20090701

• 1-[4-(N-Benzylamino)phenyl]-3-phenylurea derivatives as a new class of hypoxia-inducible factor-1alpha inhibitors.

  Bioorganic & medicinal chemistry letters 20090615

• The cyclic GMP modulators YC-1 and zaprinast reduce vessel remodeling through antiproliferative and proapoptotic effects.

  Journal of cardiovascular pharmacology and therapeutics 20090601

• [Effect of YC-1 on HIF-1 alpha and VEGF expression in human hepatocarcinoma cell lines].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20090401

• Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy.

  British journal of cancer 20090310

• YC-1 stimulates the expression of gaseous monoxide-generating enzymes in vascular smooth muscle cells.

  Molecular pharmacology 20090101

• Effect of nitric oxide/cyclic guanosine mono-phosphate pathway on gallbladder relaxant response in bile duct-ligated guinea pigs.

  European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes 20090101

• [Potentiation of nitric oxide-dependent activation of soluble guanylate cyclase by levomycetin, tetracycline, and oxolin].

  Biomeditsinskaia khimiia 20090101

• The effect of heme oxygenase inhibition on visual evoked potentials.

  The International journal of neuroscience 20090101

• A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1{alpha}.

  Molecular cancer therapeutics 20081201

• Binding of YC-1 or BAY 41-2272 to soluble guanylyl cyclase induces a geminate phase in CO photolysis.

  Journal of the American Chemical Society 20081126

• Role of the soluble guanylyl cyclase alpha1/alpha2 subunits in the relaxant effect of CO and CORM-2 in murine gastric fundus.

  Naunyn-Schmiedeberg's archives of pharmacology 20081101

• YC-1 induces apoptosis of human renal carcinoma A498 cells in vitro and in vivo through activation of the JNK pathway.

  British journal of pharmacology 20081001

• Stable expression of HIF-1alpha in tubular epithelial cells promotes interstitial fibrosis.

  American journal of physiology. Renal physiology 20081001

• YC-1 induces heat shock protein 70 expression and prevents oxidized LDL-mediated apoptosis in vascular smooth muscle cells.

  Shock (Augusta, Ga.) 20080901

• An enzyme-linked receptor mechanism for nitric oxide-activated guanylyl cyclase.

  The Journal of biological chemistry 20080704

• Design and synthesis of novel furoquinoline based inhibitors of multiple targets in the PI3K/Akt-mTOR pathway.

  Bioorganic & medicinal chemistry letters 20080615

• [Recent progress in the study on antitumor drugs targeting hypoxia-inducible factor-1].

  Yao xue xue bao = Acta pharmaceutica Sinica 20080601

• ANP stimulates hepatocyte Ca2+ efflux via plasma membrane recruitment of PKGIalpha.

  Biochemical and biophysical research communications 20080418

• YC-1 attenuates homotypic human neutrophil aggregation through inhibition of phosphodiesterase activity.

  European journal of pharmacology 20080128

• Anticancer mechanisms of YC-1 in human lung cancer cell line, NCI-H226.

  Biochemical pharmacology 20080115

• Inhibitory effect of YC-1, 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole, on experimental choroidal neovascularization in rat.

  Ophthalmic research 20080101

• Novel therapies for cyclic GMP control of vascular smooth muscle growth.

  American journal of therapeutics 20080101

• [YC-1-like potentiation of nitric oxide-dependent activation of soluble guanylyl cyclase by adrenochrome].

  Biomeditsinskaia khimiia 20080101

• Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma.

  Cancer biology & therapy 20071201

• SEPT9_V1 protein expression is associated with human cancer cell resistance to microtubule-disrupting agents.

  Cancer biology & therapy 20071201

• Synthesis of (aryloxyacetylamino)-isonicotinic/nicotinic acid analogues as potent hypoxia-inducible factor (HIF)-1alpha inhibitors.

  Bioorganic & medicinal chemistry letters 20071115

• Functional role of the soluble guanylyl cyclase alpha(1) subunit in vascular smooth muscle relaxation.

  Cardiovascular research 20071001

• Modulation of human monocyte-derived dendritic cells maturation by a soluble guanylate cyclase activator, YC-1, in a cyclic nucleotide independent manner.

  International immunopharmacology 20071001

• Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading.

  Cancer letters 20070918

• Synthesis and evaluation of a phosphonate analogue of the soluble guanylate cyclase activator YC-1.

  Bioorganic & medicinal chemistry letters 20070901

• Inhibition of hypoxia-induced increase of blood-brain barrier permeability by YC-1 through the antagonism of HIF-1alpha accumulation and VEGF expression.

  Molecular pharmacology 20070801

• Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.

  The Journal of pharmacology and experimental therapeutics 20070801

• YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia.

  Oncogene 20070607

• Regulation of soluble guanylyl cyclase activity by oestradiol and progesterone in the hypothalamus but not hippocampus of female rats.

  Journal of neuroendocrinology 20070601

• YC-1 attenuates LPS-induced proinflammatory responses and activation of nuclear factor-kappaB in microglia.

  British journal of pharmacology 20070601

• Guanylate cyclase activators influence reactivity of human mesenteric superior arteries retrieved and preserved in the same conditions as transplanted kidneys.

  Transplantation proceedings 20070601

• Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.

  Cancer research 20070501

• Investigation of the vasorelaxant effects of 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1) and diethylamine/nitric oxide (DEA/NO) on the human radial artery used as coronary bypass graft.

  Canadian journal of physiology and pharmacology 20070501

• Does nitric oxide modulate transmitter release at the mammalian neuromuscular junction?

  Clinical and experimental pharmacology & physiology 20070401

• Effects of YC-1 on hypoxia-inducible factor 1-driven transcription activity, cell proliferative vitality, and apoptosis in hypoxic human pancreatic cancer cells.

  Pancreas 20070301

• Synthesis of furopyrazole analogs of 1-benzyl-3-(5-hydroxymethyl-2-furyl)indazole (YC-1) as novel anti-leukemia agents.

  Bioorganic & medicinal chemistry 20070215

• Nitric oxide mediates natural polyphenol-induced Bcl-2 down-regulation and activation of cell death in metastatic B16 melanoma.

  The Journal of biological chemistry 20070202

• Contractile performance of adult ventricular rat cardiomyocytes is not directly jeopardized by NO/cGMP-dependent induction of pro-apoptotic pathways.

  Journal of molecular and cellular cardiology 20070201

• Nitric oxide regulates cell survival in purified cultures of avian retinal neurons: involvement of multiple transduction pathways.

  Journal of neurochemistry 20070101

• Human meniscus cells express hypoxia inducible factor-1alpha and increased SOX9 in response to low oxygen tension in cell aggregate culture.

  Arthritis research & therapy 20070101

• [Nitric oxide. Potentiation of NO-dependent activation of soluble guanylate cyclase--(patho)physiological and pharmacotherapeutical significance].

  Biomeditsinskaia khimiia 20070101

• Suppression of hypoxia inducible factor-1alpha (HIF-1alpha) by YC-1 is dependent on murine double minute 2 (Mdm2).

  Biochemical and biophysical research communications 20061006

• Chronic hypoxia promotes hypoxia-inducible factor-1alpha-dependent resistance to etoposide and vincristine in neuroblastoma cells.

  Molecular cancer therapeutics 20060901

• Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase.

  Cardiovascular research 20060715

• A domain responsible for HIF-1alpha degradation by YC-1, a novel anticancer agent.

  International journal of oncology 20060701

• [Inhibitory effect of YC-1 on induction of VEGF and GPI genes in hypoxic human pancreatic cancer cells].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20060701

• YC-1 induces S cell cycle arrest and apoptosis by activating checkpoint kinases.

  Cancer research 20060615

• Penile erection requires association of soluble guanylyl cyclase with endothelial caveolin-1 in rat corpus cavernosum.

  American journal of physiology. Regulatory, integrative and comparative physiology 20060501

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine] and YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl Indazole].

  The Journal of pharmacology and experimental therapeutics 20060401

• YC-1-like potentiation of NO-dependent activation of soluble guanylate cyclase by derivatives of protoporphyrin IX.

  Biochemistry. Biokhimiia 20060301

• Sulindac independently modulates extracellular signal-regulated kinase 1/2 and cyclic GMP-dependent protein kinase signaling pathways.

  Molecular cancer therapeutics 20060301

• The design and synthesis of YC-1 analogues as probes for soluble guanylate cyclase.

  Bioorganic & medicinal chemistry letters 20060201

• YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9.

  The Journal of pharmacology and experimental therapeutics 20060101

• Relaxant effects of the soluble guanylate cyclase activator and NO sensitizer YC-1 in piglet pulmonary arteries.

  Biology of the neonate 20060101

• Comparative relaxant effects of YC-1 and DEA/NO on the sheep sphincter of Oddi.

  Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 20060101

• BAY 41-2272, a potent activator of soluble guanylyl cyclase, stimulates calcium elevation and calcium-activated potassium current in pituitary GH cells.

  Clinical and experimental pharmacology & physiology 20051201

• Altered vascular reactivity in mice made hypertensive by nitric oxide synthase inhibition.

  Journal of cardiovascular pharmacology 20051001

• YC-1 suppresses constitutive nuclear factor-kappaB activation and induces apoptosis in human prostate cancer cells.

  Molecular cancer therapeutics 20051001

• Activation of protein kinase G up-regulates expression of 15-lipoxygenase-1 in human colon cancer cells.

  Cancer research 20050915

• Interference of neutrophil-platelet interaction by YC-1: a cGMP-dependent manner on heterotypic cell-cell interaction.

  European journal of pharmacology 20050905

• Enhanced responsiveness to nitric oxide, nitroxyl anions, and nitrergic transmitter by 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole in the rat anococcygeus muscle.

  Nitric oxide : biology and chemistry 20050901

• Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20050901

• New drugs target hypoxia response in tumors.

  Journal of the National Cancer Institute 20050803

• Nitric oxide/cyclic guanosine monophosphate signaling in the central complex of the grasshopper brain inhibits singing behavior.

  The Journal of comparative neurology 20050725

• Comparative relaxant effects of YC-1 and DETA/NO on spontaneous contractions and the levels of cGMP of isolated pregnant rat myometrium.

  European journal of pharmacology 20050711

• YC-1-inhibited proliferation of rat mesangial cells through suppression of cyclin D1-independent of cGMP pathway and partially reversed by p38 MAPK inhibitor.

  European journal of pharmacology 20050704

• Dynamic association of nitric oxide downstream signaling molecules with endothelial caveolin-1 in rat aorta.

  The Journal of pharmacology and experimental therapeutics 20050701

• YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models.

  The Journal of pharmacology and experimental therapeutics 20050701

• Nitric oxide upregulates induction of PDGF receptor-alpha expression in rat renal mesangial cells and in anti-Thy-1 glomerulonephritis.

  Journal of the American Society of Nephrology : JASN 20050701

• The nitric oxide donor sodium nitroprusside stimulates the Na+-K+ pump in isolated rabbit cardiac myocytes.

  The Journal of physiology 20050615

• Resonance Raman and infrared spectroscopic studies of high-output forms of human soluble guanylyl cyclase.

  Journal of the American Chemical Society 20050406

• Enhancement of learning behaviour by a potent nitric oxide-guanylate cyclase activator YC-1.

  The European journal of neuroscience 20050301

• CORM-A1: a new pharmacologically active carbon monoxide-releasing molecule.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20050201

• [Hypoxia-inducible factor 1: regulation, involvement in carcinogenesis and target for anticancer therapy].

  Bulletin du cancer 20050201

• Soluble guanylyl cyclase during postnatal porcine pulmonary maturation.

  American journal of physiology. Lung cellular and molecular physiology 20050101

• Nerve-induced release of nitric oxide from the rabbit corpus cavernosum is modulated by cyclic guanosine 3',5'-monophosphate.

  Neuroscience 20050101

• cAMP modulates cGMP-mediated cerebral arteriolar relaxation in vivo.

  American journal of physiology. Heart and circulatory physiology 20041201

• The blockade of cyclopiazonic acid-induced store-operated Ca2+ entry pathway by YC-1 in neutrophils.

  Biochemical pharmacology 20041115

• Salutary properties of YC-1 in the cardiovascular and hematological systems.

  Current medicinal chemistry. Cardiovascular and hematological agents 20041001

• Activation of soluble guanylyl cyclase inhibits estradiol production and cyclic AMP accumulation from cultured rat granulosa cells.

  Fertility and sterility 20041001

• New anticancer strategies targeting HIF-1.

  Biochemical pharmacology 20040915

• Soluble guanylyl cyclase is localised in the acinar cells and participates in amylase secretion in rat parotid gland.

  Archives of oral biology 20040901

• YC-1-induced cyclooxygenase-2 expression is mediated by cGMP-dependent activations of Ras, phosphoinositide-3-OH-kinase, Akt, and nuclear factor-kappaB in human pulmonary epithelial cells.

  Molecular pharmacology 20040901

• An evolutionarily conserved mechanism for sensitization of soluble guanylyl cyclase reveals extensive nitric oxide-mediated upregulation of cyclic GMP in insect brain.

  The European journal of neuroscience 20040901

• Downregulation of cGMP-dependent protein kinase expression by inflammatory cytokines in vascular smooth muscle cells.

  American journal of physiology. Cell physiology 20040701

• Resonance Raman study on synergistic activation of soluble guanylate cyclase by imidazole, YC-1 and GTP.

  Journal of inorganic biochemistry 20040501

• Versatile pharmacological actions of YC-1: anti-platelet to anticancer.

  Cancer letters 20040415

• Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272.

  Circulation 20040413

• Inhibitory mechanisms of YC-1 and PMC in the induction of iNOS expression by lipoteichoic acid in RAW 264.7 macrophages.

  Biochemical pharmacology 20040401

• Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease. Evidence for involvement of the transcription factor Egr-1.

  The Journal of biological chemistry 20040326

• Functional characterization of nitric oxide and YC-1 activation of soluble guanylyl cyclase: structural implication for the YC-1 binding site?

  Biochemistry 20040323

• The inhibitory mechanism of YC-1, a benzyl indazole, on smooth muscle cell proliferation: an in vitro and in vivo study.

  Journal of pharmacological sciences 20040301

• Antiaggregating and antithrombotic activities of new 1, 2, 3-triazolecarboxamides.

  Archiv der Pharmazie 20040301

• Involvement of the cGMP signalling pathway in the regulation of viability in insulin-secreting BRIN-BD11 cells.

  FEBS letters 20040213

• Contribution of cGMP but not peroxynitrite to negative feedback regulation of penile erection elicited by nitric oxide in the hippocampal formation of the rat.

  Neuropharmacology 20040101

• YC-1 prevents sodium nitroprusside-mediated apoptosis in vascular smooth muscle cells.

  Cardiovascular research 20040101

• YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits the spontaneous contractions of isolated pregnant rat myometrium.

  Journal of pharmacological sciences 20040101

• Mechanism of the positive contractile effect of nitric oxide on rat ventricular cardiomyocytes with positive force/frequency relationship.

  Pflugers Archiv : European journal of physiology 20031201

• Soluble guanylyl cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway.

  Molecular pharmacology 20031201

• The NO signaling pathway differentially regulates KCC3a and KCC3b mRNA expression.

  Nitric oxide : biology and chemistry 20031101

• Preparation of heme-free soluble guanylate cyclase.

  Protein expression and purification 20030901

• YC-1 inhibits proliferation of human vascular endothelial cells through a cyclic GMP-independent pathway.

  Biochemical pharmacology 20030715

• Potentiation of tumor necrosis factor-alpha expression by YC-1 in alveolar macrophages through a cyclic GMP-independent pathway.

  Biochemical pharmacology 20030701

• Nitric oxide signaling in brain: potentiating the gain with YC-1.

  Molecular pharmacology 20030601

• Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1-benzyl-indazole.

  Molecular pharmacology 20030601

• A functional domain of the alpha1 subunit of soluble guanylyl cyclase is necessary for activation of the enzyme by nitric oxide and YC-1 but is not involved in heme binding.

  The Journal of biological chemistry 20030404

• Is HIF-1 alpha a valid therapeutic target?

  Journal of the National Cancer Institute 20030402

• YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.

  Journal of the National Cancer Institute 20030402

• YC-1 facilitates release of the proximal His residue in the NO and CO complexes of soluble guanylate cyclase.

  The Journal of biological chemistry 20030328

• Inhibition by ebselen on nitric oxide mediated relaxations in the rat anococcygeus muscle.

  European journal of pharmacology 20030221

• Nitric oxide-mediated arachidonic acid release from perifused Venus verrucosa oocytes.

  General and comparative endocrinology 20030215

• Post-transcriptional regulation of soluble guanylyl cyclase expression in rat aorta.

  The Journal of biological chemistry 20030124

• A-350619: a novel activator of soluble guanylyl cyclase.

  Life sciences 20030117

• YC-1 potentiates the nitric oxide/cyclic GMP pathway in corpus cavernosum and facilitates penile erection in rats.

  European journal of pharmacology 20030101

• Analysis of nitric oxide-sensitive guanylyl cyclase in human platelets before and after aggregation.

  Platelets 20030101

• Investigation of the potential modulatory effect of biliverdin, carbon monoxide and bilirubin on nitrergic neurotransmission in the pig gastric fundus.

  European journal of pharmacology 20021220

• Inhibition of rat platelet aggregation by the diazeniumdiolate nitric oxide donor MAHMA NONOate.

  British journal of pharmacology 20021201

• 1-Benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole (YC-1) derivatives as novel inhibitors against sodium nitroprusside-induced apoptosis.

  Journal of medicinal chemistry 20021107

• Selective regulation of blood pressure by heme oxygenase-1 in hypertension.

  Hypertension (Dallas, Tex. : 1979) 20020901

• Nitric oxide potently inhibits the rate-limiting enzymatic step in steroidogenesis.

  Molecular and cellular endocrinology 20020830

• Inhibition of deactivation of NO-sensitive guanylyl cyclase accounts for the sensitizing effect of YC-1.

  The Journal of biological chemistry 20020712

• Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels.

  The Journal of pharmacology and experimental therapeutics 20020601

• YC-1 increases cyclo-oxygenase-2 expression through protein kinase G- and p44/42 mitogen-activated protein kinase-dependent pathways in A549 cells.

  British journal of pharmacology 20020601

• Nitric oxide independent activation of guanylate cyclase by YC-1 causes erectile responses in the rat.

  The Journal of urology 20020501

• Pharmacology of the nitric oxide receptor, soluble guanylyl cyclase, in cerebellar cells.

  British journal of pharmacology 20020501

• The nitric oxide donor NOC12 protects cultured astrocytes against apoptosis via a cGMP-dependent mechanism.

  Japanese journal of pharmacology 20020501

• Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.

  The Journal of biological chemistry 20020419

• BAY 41-2272 activates two isoforms of nitric oxide-sensitive guanylyl cyclase.

  Biochemical and biophysical research communications 20020412

• Carbon monoxide relaxes the female pig urethra as effectively as nitric oxide in the presence of YC-1.

  The Journal of urology 20020401

• Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1.

  International journal of impotence research 20020401

• YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and platelet function.

  Biochemical and biophysical research communications 20020308

• Nitric oxide modulates endotoxin-induced platelet-endothelial cell adhesion in intestinal venules.

  American journal of physiology. Heart and circulatory physiology 20020301

• Insulin increases NADH/NAD+ redox state, which stimulates guanylate cyclase in vascular smooth muscle.

  American journal of hypertension 20020301

• Inhibition of superoxide anion generation by YC-1 in rat neutrophils through cyclic GMP-dependent and -independent mechanisms.

  Biochemical pharmacology 20020215

• Comparison of nitric oxide donors in lowering intraocular pressure in rabbits: role of cyclic GMP.

  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20020201

• Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction.

  International journal of impotence research 20020201

• Soluble guanylyl cyclase activator YC-1 protects white matter axons from nitric oxide toxicity and metabolic stress, probably through Na(+) channel inhibition.

  Molecular pharmacology 20020101

• Carbon monoxide decreases perfusion pressure in isolated human placenta.

  Placenta 20020101

• Effect of nitric oxide on arachidonic acid release from human amnion-like WISH cells.

  Placenta 20020101

• Role of conformational changes in the heme-dependent regulation of human soluble guanylate cyclase.

  Journal of inorganic biochemistry 20011215

• Prolonged exposure to YC-1 induces apoptosis in adrenomedullary endothelial and chromaffin cells through a cGMP-independent mechanism.

  Neuropharmacology 20011201

• Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells.

  The Journal of pharmacology and experimental therapeutics 20011101

• Synthesis of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole analogues as novel antiplatelet agents.

  Journal of medicinal chemistry 20011025

• Organic phosphates as a new class of soluble guanylate cyclase inhibitors.

  FEBS letters 20011019

• Inhibition of extracellular Ca(2+) entry by YC-1, an activator of soluble guanylyl cyclase, through a cyclic GMP-independent pathway in rat neutrophils.

  Biochemical pharmacology 20010915

• Inhibition of glucose transport by cyclic GMP in cardiomyocytes.

  Life sciences 20010810

• In vitro activation of soluble guanylyl cyclase and nitric oxide release: a comparison of NO donors and NO mimetics.

  Biochemistry 20010807

• Synergism between nitric oxide and hydrogen peroxide in the inhibition of platelet function: the roles of soluble guanylyl cyclase and vasodilator-stimulated phosphoprotein.

  Nitric oxide : biology and chemistry 20010601

• Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells.

  Biochemical pharmacology 20010415

• Vinpocetine-induced stimulation of calcium-activated potassium currents in rat pituitary GH3 cells.

  Biochemical pharmacology 20010401

• NO-independent stimulators of soluble guanylate cyclase.

  Bioorganic & medicinal chemistry letters 20010326

• NO-independent regulatory site on soluble guanylate cyclase.

  Nature 20010308

• Molecular mechanisms involved in the synergistic activation of soluble guanylyl cyclase by YC-1 and nitric oxide in endothelial cells.

  Molecular pharmacology 20010201

• Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase.

  Journal of medicinal chemistry 20010104

• YC-1 enhances the responsiveness of tolerant vascular smooth muscle to glyceryl trinitrate.

  Canadian journal of physiology and pharmacology 20010101

• Altered content and modulation of soluble guanylate cyclase in the cerebellum of rats with portacaval anastomosis.

  Neuroscience 20010101

• NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272.

  BMC pharmacology 20010101

• Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20001001

• Functional properties of a naturally occurring isoform of soluble guanylyl cyclase.

  The Biochemical journal 19981001

• Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme.

  The EMBO journal 19961216

• YC-1, a novel activator of platelet guanylate cyclase.

  Blood 19941215